Uta Frith


Uta Frith studied experimental psychology at the Universität des Saarlandes, Saarbrücken and trained in clinical psychology at the University of London’s Institute of Psychiatry She completed her Ph.D. thesis on autism in 1968 and from then on has worked as a research scientist funded mainly by the Medical Research Council UK. She has been Visiting Professor at the University of Aarhus, Denmark from 2007-2015. She is now Emeritus Professor of Cognitive Development at the UCL Institute of Cognitive Neuroscience.
Autism and dyslexia have been her main focus of research. In both fields she has pioneered an experimental neuropsychological approach. She has contributed some of the major theories explaining these disorders and has identified specific deficits in underlying cognitive mechanisms and their basis in the brain. She has published some 250 papers and books, and in 2014 she was listed by the APA as among the 200 most eminent psychologists of the modern era.
In the last few years she has increased her work in science communication, and in championing women in science.

From this contributor

Explore more from The Transmitter

Headshots of Yale researchers Yong-Hui Jiang and Jiangbing Zhou.

Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions

Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.

By Natalia Mesa
3 June 2026 | 11 min read

What counts as a ‘naturalistic’ behavior?

Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.

By Paul Middlebrooks
3 June 2026 | 1 min read
Research image of brain cells involved with Amyotrophic lateral sclerosis (ALS) illuminated through genetic tools

Allen Institute sets sights on treatments for five brain diseases

The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.

By Calli McMurray
2 June 2026 | 5 min read